A FAERS database analysis of suicidal tendencies associated with GLP-1 RAs showed disproportionate reports of suicidal ideation and “depression/suicide” for semaglutide and liraglutide, but no disproportionate signals for suicidal behavior, attempted suicide, or suicide death across all FDA-approved GLP-1 RAs [48]. This evidence concerns the gene GLP1R and depressive disorder.